AFP and hepatocellular carcinoma: As reported by Tomimaru et al., the combination of plasma miR-21 and AFP has an AUC of 0.971 in discriminating HCC from healthy controls, and an AUC of 0.823 in discriminating HCC from patients with chronic hepatitis31, which has far better performance than AFP alone.